Skip To Main Content
Yihebali Chi on Muck Rack

Yihebali Chi

As seen in: Frontiers, EClinicalMedicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yihebali

Contact Yihebali, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of bevacizumab plus XELOX in patients with unresectable locally advanced or metastatic neuroendocrine tumors

|
By Huike Wang, Huijing Tan, Yuting Sun, Yanwei Su, Yihebali Chi
| Frontiers
Abstract Neuroendocrine tumors (NETs) are highly vascularized malignancies for which effective treatment options remain limited in the unresectable locally advanced or metastatic setting. Although platinum-based chemotherapy has demonstrated antitumor activity in advanced NETs, evidence supporting its combination with antiangiogenic therapy remains insufficient.
Open in Who Shared Issue with article?

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial

|
By Yihebali Chi, Lijie Song, Weili Liu
| EClinicalMedicine Verified
Summary Background There are currently limited systemic treatment options for patients with advanced neuroendocrine tumours (NETS) and the efficacy of existing treatments is sub-optimal. We evaluated the efficacy and safety of Tegafur/gimeracil/oteracil/potassium capsules (S-1)/Temozolomide with or without thalidomide for the treatment of NETS (STEM trial). Methods A randomised, controlled, open-label, phase 2 trial conducted at eight hospitals in China.
Open in Who Shared Issue with article?

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

|
By Dapeng Li, Yihebali Chi, Xiaohong Chen, Ming-Hua Ge
| AACR Journal
Research Article Dapeng Li, Yihebali Chi, Xiaohong Chen, Ming-Hua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng, Zhengang Xu, Xiangqian Zheng, Pingzhang Tang and Ming Gao DOI: 10.1158/1078-0432.CCR-20-2950 Abstract Purpose: Medullary thyroid cancer (MTC) accounts for about 2% of all thyroid cancer, but has a relatively poor prognosis compared with differentiated thyroid cancer.
Open in Who Shared Issue with article?
See all 4 articles